TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8114055
Drug: Individual basis
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual basis administered by physician‐nurse teams (PN)
Study: 3534198
Drug: Glycine-based oral
Normalized name: glycine Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine-based oral rehydration solution (glycine-ORS)
Study: 3534198
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral rehydration solution (ORS)
Study: 24531083
Drug: NSAID-GGA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID-GGA group (75 mg/day diclofenac sodium and 150 mg/day GGA)
Study: 24531083
Drug: NSAID-FAM group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID-FAM group (75 mg/day diclofenac sodium and 20 mg/day famotidine)
Study: 24327533
Drug: Bilateral coronoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral coronoid hyperplasia treatment group
Study: 19022973
Drug: Zinc (10-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (10-mg tablets daily until discharge)
Study: 19022973
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily until discharge)
Study: 16649407
Drug: S-adenosyl-L-methione (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methione (SAMe) 500mg twice daily in slow running infusion for twelve days, ongoing oral 500 mg twice daily until delivery
Study: 16649407
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 3 x 250 mg daily
Study: 16649407
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with both drugs (SAMe and UDCA)
Study: 16649407
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (SAMe monotherapy)
Study: 12794404
Drug: 7.5% hypertonic
Normalized name: SODIUM CHLORIDE 7.5 g in 100 mL ORAL LIQUID [7.5% Hypertonic Saline]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% hypertonic saline solution (2400 mOsm/kg/H(2)O)
Study: 6588485
Drug: Metronidazole (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1500 mg)
Study: 6588485
Drug: Tinidazole (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (1600 mg)
Study: 30580680
Drug: Intensive BP
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive BP treatment (systolic BP target, <120 mm Hg)
Study: 30580680
Drug: Standard BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BP treatment (systolic BP target, <140 mm Hg)
Study: 23888450
Drug: Vaseline ointment
Normalized name: petrolatum Topical Ointment [Vaseline]
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaseline ointment (control)
Study: 21444807
Drug: High-dose CNTF
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CNTF implant
Study: 21444807
Drug: Low-dose CNTF
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CNTF implant
Study: 21444807
Drug: Combined low-dose/sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined low-dose/sham group
Study: 19802659
Drug: Fondaparinux sodium
Normalized name: Fondaparinux Sodium
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaparinux sodium (FPX) 2.5 mg/day for 14 days
Study: 27068249
Drug: Rate control
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate control therapy
Study: 14618033
Drug: Rhythm control
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm control therapy
Study: 3553496
Drug: Captopril (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (with diuretic)
Study: 3553496
Drug: Methyldopa (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (with diuretic)
Study: 3553496
Drug: Propranolol (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (with diuretic)
Study: 22142346
Drug: Triple-combination therapy
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-combination therapy (Olmesartan 40 mg, Amlodipine 10 mg, Hydrochlorothiazide 25 mg)
Study: 22142346
Drug: Dual-combination (Olmesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-combination (Olmesartan 40 mg + Amlodipine 10 mg)
Study: 22142346
Drug: Dual-combination (Olmesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-combination (Olmesartan 40 mg + Hydrochlorothiazide 25 mg)
Study: 22142346
Drug: Dual-combination (Amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-combination (Amlodipine 10 mg + Hydrochlorothiazide 25 mg)
Study: 20225470
Drug: F dentifrice
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: F dentifrice (1500 microg F/g as sodium monofluorophosphate)
Study: 12411789
Drug: ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (4 mg intravenous) with sham ReliefBand
Study: 12411789
Drug: acustimulation (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: acustimulation (saline 2 ml intravenous) with active ReliefBand
Study: 12411789
Drug: ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (4 mg intravenous) with active ReliefBand
Study: 7661353
Drug: CSE with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSE with 40 mg intrathecal 2% lidocaine
Study: 7661353
Drug: CSE with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSE with 60 mg intrathecal 2% lidocaine
Study: 7661353
Drug: CSE with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSE with 80 mg intrathecal 2% lidocaine
Study: 2669718
Drug: 10% povidone-iodine
Normalized name: POVIDONE-IODINE 100 mg in 1 mL TOPICAL LIQUID [Saninta 10% Povidone-Iodine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% povidone-iodine pre-operative preparation for 12 hours
Study: 2669718
Drug: Pre-operative antiseptic
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative antiseptic preparation
Study: 770363
Drug: Pimozide at
Normalized name: Pimozide
DrugBank: Pimozide (DB01100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimozide at doses of 2 mg/day
Study: 770363
Drug: Diazepam at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam at doses of 3 x 5 mg
Study: 28385672
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy with shocks
Study: 28385672
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy with ATP
Study: 24101169
Drug: Sentinel lymph
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy
Study: 15197201
Drug: Fluorouracil-based combination
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil-based combination chemotherapy
Study: 11473559
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg kg‐1 (group L)
Study: 9710337
Drug: Intensive acupuncture
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive acupuncture (25 treatment sessions over 2 months, each lasting 30 minutes)
Study: 25794439
Drug: Fortified yogurt
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fortified yogurt (FY; 2000 IU vitamin D in 100 g/day)
Study: 17327864
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (5.9 g/day total n‐3 fatty acids; 1.8 g 20:5n‐3, 3.0 g 22:6n‐3)
Study: 17327864
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (8.5 g/day 18:2n‐6 FA)
Study: 14653832
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate (30 mg) in combination with oral calcium (500 mg) and vitamin D (400 IU)
Study: 14653832
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium (500 mg) and vitamin D (400 IU) alone
Study: 1354411
Drug: 0.1% ophthalmic
Normalized name: Vevye 0.1% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ophthalmic solution of 8-hydroxycarteolol
Study: 1354411
Drug: 0.01%, 0.1%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01%, 0.1%, 0.5%, and 1% ophthalmic solutions of 8-hydroxycarteolol
Study: 30583518
Drug: Navy bean
Normalized name: navy bean
DrugBank: Kidney bean (DB10639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navy bean consumption (35 g of cooked navy bean daily)
Study: 30583518
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 g of navy beans)
Study: 26323560
Drug: Bicalutamide 150
Normalized name: bicalutamide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150 mg for 9 months
Study: 20720255
Drug: Standardized meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized meal (providing 50% of the daily estimated energy requirements)
Study: 2007100
Drug: Parascalene block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parascalene block with 0.5 ml/kg 0.25% bupivacaine with 1:200,000 epinephrine
Study: 2007100
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (subcutaneous needle puncture only)
Study: 7034757
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 1.5 ml in 8% glucose
Study: 7034757
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 2 ml in 8% glucose
Study: 7034757
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 3 ml in 8% glucose
Study: 22810435
Drug: Cytokine levels
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine levels (INF‐γ, TNF‐α, MIP‐1β, G‐CSF, MCP‐1β)
Study: 15745927
Drug: hGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH treatment (0.23 mg/kg per week)
Study: 14608063
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid plus iron (60 mg)
Study: 14608063
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid plus iron and zinc (30 mg)
Study: 9201091
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg intravenously daily (N = 35)
Study: 9201091
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg daily orally or by nasogastric route (N = 32)
Study: 8382712
Drug: Intensified dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified dietary therapy (12 months of intensified education)
Study: 8382712
Drug: Intensified dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified dietary therapy
Study: 8382712
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (visits to local health centers)
Study: 3097701
Drug: Methylphenidate (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (active drug)
Study: 30293597
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2000 mg)
Study: 16140519
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine plus fentanyl (8 mL of 0.125% solution plus fentanyl 50 microg, maintained with 0.0625% solution with fentanyl 2 microg/mL)
Study: 16140519
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine plus fentanyl (8 mL of 0.125% solution plus fentanyl 50 microg, maintained with 0.0625% solution with fentanyl 2 microg/mL)
Study: 10072025
Drug: Propofol-thiopental combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-thiopental combination
Study: 10072025
Drug: Midazolam-thiopental combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam-thiopental combination
Study: 10072025
Drug: Propofol-midazolam combination
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-midazolam combination
Study: 7482079
Drug: Surfactant replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant replacement therapy (SRT) at 3-4 hours after birth
Study: 7482079
Drug: Surfactant replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant replacement therapy (SRT) at 6-8 hours after birth
Study: 2345837
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (twice yearly)
Study: 31518424
Drug: 25(OH)D3 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D3 (10 µg/d)
Study: 31518424
Drug: 25(OH)D3 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D3 (15 µg/d)
Study: 31518424
Drug: 25(OH)D3 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D3 (20 µg/d)
Study: 31518424
Drug: D3 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 (20 µg/d)
Study: 26432181
Drug: TEV-48125 675/225
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEV-48125 675/225 mg
Study: 26432181
Drug: TEV-48125 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEV-48125 900 mg
Study: 24224471
Drug: anti-OX40L monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-OX40L monoclonal antibody (MAb)
Study: 24224471
Drug: anti-OX40L monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-OX40L monoclonal antibody (MAb) and placebo
Study: 17023874
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) users
Study: 17023874
Drug: Non-hormone therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-hormone therapy (non-HT) users
Study: 10210789
Drug: Continuous monotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous monotherapy
Study: 1983499
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapy with clomethiazol and haloperidol (group 1)
Study: 1983499
Drug: Continuous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous ethanol infusions (2‐4 g/h) postoperatively as prophylaxis for WS (group 2)
Study: 7073790
Drug: Colestipol 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 0.125 g/kg body weight
Study: 7073790
Drug: Colestipol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 0.25 g/kg body weight
Study: 31311018
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion hemodiafiltration (I-HDF)
Study: 25534747
Drug: Triflusal 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal 900 mg loading dose on Day 1, followed by 600 mg/day from Day 2 to 9
Study: 21134450
Drug: Tdap (Boostrix®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap (Boostrix® GlaxoSmithKline) and MCV4 (Menactra®, Sanofi‐Pasteur) co-administered
Study: 21134450
Drug: Tdap (Boostrix®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap (Boostrix® GlaxoSmithKline) and MCV4 (Menactra®, Sanofi‐Pasteur) administered sequentially one month apart
Study: 19758646
Drug: 20 gm
Normalized name: HYQVIA 20 GM / 200 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 gm soy protein containing 160 mg total isoflavones
Study: 12510944
Drug: Ibuprofen (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (up to 1.2 g daily)
Study: 12510944
Drug: Aspirin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (up to 3 g daily)
Study: 12510944
Drug: Paracetamol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (up to 3 g daily)
Study: 26892284
Drug: Post‐treatment infarct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post‐treatment infarct volume
Study: 7796057
Drug: 0.17-0.34- or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.17-0.34- or 0.51-M sucrose solution (2 ml)
Study: 7796057
Drug: Water (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (2 ml)
Study: 6963074
Drug: Intravenous PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous PGE2
Study: 6963074
Drug: Intravenous sulprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous sulprostone (2 schedules)
Study: 6963074
Drug: Intramuscular sulprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular sulprostone (2 schedules)
Study: 30933354
Drug: First-line platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line platinum-based chemotherapy (carboplatin in combination with nab-paclitaxel or solvent-based paclitaxel)
Study: 28053292
Drug: Polyphenon E®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenon E® (PolyE®) containing 200 mg EGCG administered with food, BID
Study: 25056277
Drug: 11.25 mg
Normalized name: phentermine 11.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.25 mg of 0.75% intrathecal hyperbaric bupivacaine
Study: 25056277
Drug: 15.0 mg
Normalized name: RUXOLITINIB 15.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15.0 mg of 0.75% intrathecal hyperbaric bupivacaine
Study: 31951273
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (casts)
Study: 21752292
Drug: Aerosolized mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized mixed oil preparation (aloe, coconut, orange, peppermint, vitamin E)
Study: 21752292
Drug: Aerosolized mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized mixed oil preparation
Study: 14706058
Drug: Bedtime diazoxide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime diazoxide, 100 mg
Study: 11034946
Drug: Cardiac troponin
Normalized name: Cardiac troponin I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac troponin T >0.10 ng/mL
Study: 11034946
Drug: Baseline glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline glucose (1 mmol/L increase)
Study: 11034946
Drug: Baseline triglycerides
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline triglycerides (1 mmol/L increase)
Study: 8810610
Drug: TGF-beta release
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF-beta release in BAL cell culture (n=12; 1,422 +/- 215 pg/ml; p < 0.004)
Study: 8810610
Drug: TGF-beta release
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF-beta release in BAL cell culture (n=21; 677 +/- 159 pg/ml)
Study: 8810610
Drug: TGF-beta release
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF-beta release in BAL cell culture (n=6; 762 +/- 419 pg/ml)
Study: 8810610
Drug: TGF-beta release
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF-beta release in BAL cell culture (n=5; 1,560 +/- 353 pg/ml)
Study: 8810610
Drug: TGF-beta release
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF-beta release in BAL cell culture (612 +/- 261.2 pg/ml)
Study: 1565532
Drug: Erythromycin estolate
Normalized name: Erythromycin Estolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin estolate (EST) 40 mg/kg/day divided in 2 doses
Study: 1565532
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (ETH) 60 mg/kg/day divided in 3 doses
Study: 24456026
Drug: Sirolimus with
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus with reduced-dose tacrolimus (loading dose: 15 mg, initial dose: 5 mg titrated to a trough of 4-11 ng/mL; reduced-dose tacrolimus trough: 3-7 ng/mL)
Study: 24456026
Drug: Sirolimus with
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus with reduced-dose tacrolimus
Study: 24456026
Drug: Conventional-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose tacrolimus (trough: 7-15 ng/mL)
Study: 24456026
Drug: Conventional-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose tacrolimus
Study: 19043140
Drug: Rosuvastatin and
Normalized name: rosuvastatin and ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin and Atorvastatin (comparison)
Study: 19043140
Drug: Rosuvastatin and
Normalized name: rosuvastatin and ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin and Atorvastatin (absolute values)
Study: 12725580
Drug: Ivy leaf
Normalized name: Ivy leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivy leaf extract syrup
Study: 12725580
Drug: Ivy leaf
Normalized name: Ivy leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivy leaf extract suppositories
Study: 3963154
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and scopolamine